{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VRC07-523LS", "query": { "intervention": "VRC07-523LS" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 24, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VRC07-523LS&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T00:12:09.578Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05719441", "title": "A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute HIV Infection" ], "interventions": [ { "name": "VRC07-523LS", "type": "BIOLOGICAL" }, { "name": "PGT121.414.LS", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" }, { "name": "ART", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 48, "start_date": "2024-08-19", "completion_date": "2028-09-06", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-04T00:12:09.578Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05719441" }, { "nct_id": "NCT02140255", "title": "Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "Nucleoside Reverse Transcriptase Inhibitors (NRTIs)", "type": "DRUG" }, { "name": "Nevirapine (NVP)", "type": "DRUG" }, { "name": "Lopinavir/Ritonavir (LPV/r)", "type": "DRUG" }, { "name": "Raltegravir (RAL)", "type": "DRUG" }, { "name": "VRC01", "type": "DRUG" }, { "name": "Dolutegravir (DTG)", "type": "DRUG" }, { "name": "VRC07-523LS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "48 Hours", "sex": "ALL", "summary": "Up to 48 Hours" }, "enrollment_count": 1120, "start_date": "2015-01-23", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-09-04T00:12:09.578Z", "location_count": 20, "location_summary": "La Jolla, California • Los Angeles, California • Aurora, Colorado + 13 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02140255" }, { "nct_id": "NCT05184452", "title": "A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "PGDM1400LS (5mg/kg, IV)", "type": "DRUG" }, { "name": "PGDM1400LS (20mg/kg, IV)", "type": "DRUG" }, { "name": "PGDM1400LS (20mg/kg, SC)", "type": "DRUG" }, { "name": "PGDM1400LS (40mg/kg, IV)", "type": "DRUG" }, { "name": "PGDM1400LS (40mg/kg, SC)", "type": "DRUG" }, { "name": "PGDM1400LS (1.4g, IV)", "type": "DRUG" }, { "name": "PGDM1400LS (1.4g, SC)", "type": "DRUG" }, { "name": "VRC07-523LS (20mg/kg, IV)", "type": "DRUG" }, { "name": "VRC07-523LS (20mg/kg, SC)", "type": "DRUG" }, { "name": "VRC07-523LS (1.4g, IV)", "type": "DRUG" }, { "name": "VRC07-523LS (1.4g, SC)", "type": "DRUG" }, { "name": "VRC07-523LS (40mg/kg, IV)", "type": "DRUG" }, { "name": "PGT121.414.LS (20mg/kg, IV)", "type": "DRUG" }, { "name": "PGT121.414.LS (20mg/kg, SC)", "type": "DRUG" }, { "name": "PGT121.414.LS (1.4g, IV)", "type": "DRUG" }, { "name": "PGT121.414.LS (1.4g, SC)", "type": "DRUG" }, { "name": "PGT121.414.LS (40mg/kg, IV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 95, "start_date": "2021-11-15", "completion_date": "2023-07-19", "has_results": true, "last_update_posted_date": "2025-02-10", "last_synced_at": "2026-09-04T00:12:09.578Z", "location_count": 5, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Newark", "state": "New Jersey" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05184452" }, { "nct_id": "NCT07215468", "title": "HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV -1 Infection" ], "interventions": [ { "name": "TMB-365", "type": "DRUG" }, { "name": "TMB-380", "type": "DRUG" }, { "name": "Baseline ART", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TaiMed Biologics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2025-12-16", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-04T00:12:09.578Z", "location_count": 10, "location_summary": "San Francisco, California • Fort Lauderdale, Florida • Ft. Pierce, Florida + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Miami Gardens", "state": "Florida" }, { "city": "Oakland Park", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07215468" }, { "nct_id": "NCT02256631", "title": "Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "VRC01", "type": "BIOLOGICAL" }, { "name": "VRC01LS", "type": "BIOLOGICAL" }, { "name": "VRC07-523LS", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Days", "maximum_age": "5 Days", "sex": "ALL", "summary": "0 Days to 5 Days" }, "enrollment_count": 83, "start_date": "2015-06-30", "completion_date": "2021-12-16", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-09-04T00:12:09.578Z", "location_count": 10, "location_summary": "Los Angeles, California • Aurora, Colorado • Fort Lauderdale, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02256631" }, { "nct_id": "NCT03015181", "title": "VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Prevention" ], "interventions": [ { "name": "VRC-HIVMAB075-00-AB", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 26, "start_date": "2017-02-21", "completion_date": "2018-07-10", "has_results": true, "last_update_posted_date": "2020-10-26", "last_synced_at": "2026-09-04T00:12:09.578Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03015181" }, { "nct_id": "NCT04340596", "title": "Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "N-803 (IL-15 Superagonist)", "type": "BIOLOGICAL" }, { "name": "VRC07-523LS", "type": "BIOLOGICAL" }, { "name": "10-1074", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 118, "start_date": "2021-05-21", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-04T00:12:09.578Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04340596" }, { "nct_id": "NCT04357821", "title": "Combinatorial Therapy to Induce an HIV Remission", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV/AIDS" ], "interventions": [ { "name": "Combination Intervention", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "67 Years", "sex": "ALL", "summary": "18 Years to 67 Years" }, "enrollment_count": 11, "start_date": "2020-08-01", "completion_date": "2025-06-12", "has_results": true, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-04T00:12:09.578Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04357821" }, { "nct_id": "NCT07390955", "title": "A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV" ], "interventions": [ { "name": "ePGT121v1-LS (IV)", "type": "BIOLOGICAL" }, { "name": "PGDM1400LS (IV)", "type": "BIOLOGICAL" }, { "name": "VRC07-523LS (IV)", "type": "BIOLOGICAL" }, { "name": "ePGT121v1-LS (SC)", "type": "BIOLOGICAL" }, { "name": "PGDM1400LS (SC)", "type": "BIOLOGICAL" }, { "name": "VRC07-523LS (SC)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 83, "start_date": "2026-03-19", "completion_date": "2027-08-30", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-04T00:12:09.578Z", "location_count": 7, "location_summary": "Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07390955" }, { "nct_id": "NCT04983030", "title": "Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV", "Acquired Immunodeficiency Syndrome", "Immunologic Deficiency Syndrome, Acquired", "Sexually Transmitted Diseases, Viral", "Retroviridae Infections" ], "interventions": [ { "name": "Ad26.Mos4.HIV", "type": "BIOLOGICAL" }, { "name": "MVA-BN-HIV", "type": "BIOLOGICAL" }, { "name": "PGT121", "type": "BIOLOGICAL" }, { "name": "PGDM1400", "type": "BIOLOGICAL" }, { "name": "VRC07-523LS", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Boris Juelg, MD PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 28, "start_date": "2022-04-01", "completion_date": "2026-02-23", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-09-04T00:12:09.578Z", "location_count": 6, "location_summary": "Los Angeles, California • Orlando, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04983030" } ] }